The treatment of tumor cells with luteinizing hormone, follicle-stimulating hormone, estrogen, and progesterone induced significant changes in Sema3B and Sema3F expression (106), implying that gonadotropin- and/or estrogen-mediated maintenance of Sema3 expression could control ovarian cancer angiogenesis and metastasis. The gene discussed is SEMA3F; the disease is ovarian cancer.